Anteris Announces Results for the First Quarter of 2026
Rhea-AI Summary
Anteris (NASDAQ/ASX: AVR) reported Q1 2026 results and clinical progress. The company completed $320 million in capital raises in January 2026 to fund the PARADIGM pivotal trial and advance DurAVR® THV commercialization.
PARADIGM enrollment continued in Europe and began in the U.S., supported by a CMS TAVR coverage determination. Net operating cash outflows were $28.7 million, including $17.5 million in R&D expenses focused on manufacturing scale-up and trial-related activities. Anteris also presented new DurAVR® clinical data from the EMBARK and U.S. Early Feasibility studies at CRT 2026 and Sydney Valves 2026.
Positive
- $320 million capital raised in January 2026 for PARADIGM and commercialization
- PARADIGM global pivotal trial enrollment active in Europe and United States
- CMS TAVR NCD 20.32 coverage supports U.S. PARADIGM site adoption and recruitment
- R&D spend $17.5m focused on manufacturing, quality scale-up and PARADIGM activities
- DurAVR clinical data presented from EMBARK and U.S. Early Feasibility studies
Negative
- Net operating cash outflow of $28.7m in Q1 2026
- Elevated R&D and clinical costs linked to PARADIGM Trial activities
News Market Reaction – AVR
In the May 13 session, AVR declined 2.54%, reflecting a moderate negative market reaction. Argus tracked a trough of -2.6% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | 2025 full-year results | Positive | +2.7% | 2025 results with pivotal PARADIGM initiation and strong DurAVR clinical outcomes. |
| Nov 12 | Q3 2025 results | Negative | -2.6% | Q3 2025 update showing higher cash outflows while scaling PARADIGM and manufacturing. |
| Aug 11 | Q2 2025 results | Positive | +6.0% | Q2 2025 earnings highlighting DurAVR patient growth and PARADIGM site expansion. |
| May 13 | Q1 2025 results | Negative | -9.9% | Q1 2025 results with rising net loss and declining net sales despite trial progress. |
| Mar 12 | 2024 full-year results | Negative | -6.2% | 2024 update combining U.S. IPO and trial prep with sizeable net loss and cash burn. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings releases have consistently driven price moves that align with the overall tone of the updates, often skewing negative but with occasional strong positive reactions when clinical or strategic milestones are emphasized.
Across prior earnings events from 2024–2025, Anteris used results updates to highlight DurAVR® THV progress, regulatory milestones, and pivotal PARADIGM Trial preparation. These included advancing from planning to global pivotal execution, scaling manufacturing, and disclosing cash burn and funding needs. Market reactions around these earnings ranged from sharp declines (e.g., Q1 2025) to solid gains when clinical traction and capital strength were foregrounded. Today’s Q1 2026 update continues that pattern, emphasizing PARADIGM recruitment and previously completed $320M capital raises.
Key Terms
centers for medicare and medicaid services (cms) regulatory
national coverage determination regulatory
early feasibility study (efs) medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS and BRISBANE, Australia, May 12, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update.
Q1 2026 Highlights
- Completed aggregate capital raises totalling
$320 million in January 2026 to support execution of the PARADIGM Trial and advance the Company toward global commercialization of the DurAVR® THV System - Advanced PARADIGM Trial recruitment, supported by ongoing regulatory and operational work to activate additional countries and sites – post quarter-end, U.S. enrollment commenced
- Presented clinical data from the ongoing EMBARK Study and U.S. Early Feasibility Study (EFS) at Cardiovascular Research Technologies (CRT 2026) and Sydney Valves 2026, supporting ongoing scientific engagement and exchange with the clinical community
“Q1 2026 reflects strong execution across the PARADIGM Trial, with patient enrollment ongoing in Europe and continued progress on key recruitment activities globally. With the U.S. now on line and first patients enrolled, we are firmly executing our strategy and building momentum toward the commercial launch of DurAVR®,” said Wayne Paterson, Vice Chairman and Chief Executive Officer of Anteris.
Business & Operations
Following initiation of our global pivotal trial in Q4 2025, we are seeing continued progress across Europe, and the United States where patient enrollment has recently commenced.
Clinical centers are advancing through key start up milestones, including ethics and regulatory approvals, site initiation visits and investigator training, alongside active patient screening and enrollment at activated sites.
In the United States, recent coverage determination by the Centers for Medicare and Medicaid Services (CMS) is expected to facilitate patient recruitment by supporting reimbursement and facilitating site-level adoption. Eligible procedures performed at participating U.S. study sites are covered under the Transcatheter Aortic Valve Replacement (TAVR) National Coverage Determination 20.32.
Collectively, these activities are supporting growing enrollment momentum as additional sites come on line and contribute to trial execution.
Financial Results
The financial results for Anteris for the quarter ended March 31, 2026, are presented below. All amounts in $ refer to U.S. dollars.
The Company’s net operating cash outflows for the three months ended March 31, 2026, were
Anteris refers to the detailed financial information contained in its Form 10-Q filing including the Management Discussion & Analysis and the Risks.
ENDS
About the PARADIGM Trial
The PARADIGM Trial is a prospective randomized controlled trial which will evaluate the safety and effectiveness of the DurAVR® Transcatheter Heart Valve (“THV”) compared to commercially available transcatheter aortic valve replacements (TAVRs).
This head-to-head study will enrol approximately 1,000 patients in the ‘All Comers Randomized Cohort' with 1:1 randomization of patients who will receive either the DurAVR® THV or TAVR using commercially available and approved THVs. The PARADIGM Trial will assess non-inferiority on a primary composite endpoint of all-cause mortality, all stroke and cardiovascular hospitalization at one year post procedure.
For further information, please refer to ClinicalTrials.gov NCT07194265.
About Anteris
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.
Anteris’ lead product, the DurAVR® THV, was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System.
Forward-Looking Statements
This announcement contains forward-looking statements, including statements regarding the expectation that achievement of CMS coverage will facilitate U.S. site activation, accelerating operational momentum across participating centers, and the PARADIGM Trial. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ Annual Report on Form 10-K for the fiscal period ended December 31, 2025 that was filed with the Securities and Exchange Commission and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.
For more information:
| Global Investor Relations | Investor Relations (US) |
| investors@anteristech.com | mchatterjee@bplifescience.com |
| Debbie Ormsby | Malini Chatterjee, Ph.D. |
| Anteris Technologies Global Corp. | Blueprint Life Science Group |
| +61 1300 550 310 | +61 7 3152 3200 | +1 917 330 4269 |
| Website | www.anteristech.com |
| X | @AnterisTech |
| https://www.linkedin.com/company/anteristech |
